Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that causes the progressive loss of motor neurons, which ...
High-dose dazucorilant showed significant survival benefit in a Phase 2 ALS trial. It reduced mortality risk by up to 87% over two years for ALS patients. A pivotal Phase 3 trial for this ALS therapy ...
In honor of May being ALS Awareness Month, the 37-year-old content creator has been answering viewers questions about her ...
A new drug may slow progression of -- and even reverse -- symptoms of a rare form of amyotrophic lateral sclerosis, or ALS, a new study published Monday finds. The drug, tofersen, targets a very ...
Amyotrophic lateral sclerosis (ALS) remains one of the most devastating and biologically elusive neurodegenerative diseases. Despite decades of research, its underlying mechanisms are still not fully ...
There could be new hope for ALS management as a promising drug enters phase 3 clinical trials. ALS is a progressive disease in which the brain loses connection with the muscles, The ALS Association ...
Masitinib treatment for ALS led to 42% of patients in a clinical trial surviving five years, nearly double historical rates, ...
Some patients with a rare form of ALS benefited from an experimental therapy, with biomarker evidence of reduced injury to neurons and even limited functional recovery. When Columbia neurologist and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results